Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible

Abstract Background The purpose of this study was to analyze the treatment efficacy and safety of stereotactic ablative body radiotherapy (SABR) boost for cervical cancer patients not amenable to brachytherapy. Methods A retrospective review of the medical records from single institution of 25 eligi...

Full description

Bibliographic Details
Main Authors:	Tae Hoon Lee, Changhoon Song, In Ah Kim, Jae-Sung Kim, Yong Beom Kim, Kidong Kim, Jae Hong No, Dong Hoon Suh, Jin-Beom Chung, Keun-Yong Eom
Format:	Article
Language:	English
Published:	BMC 2021-08-01
Series:	Radiation Oncology
Subjects:	Cervical cancer Stereotactic body radiotherapy Hematuria Hematochezia
Online Access:	https://doi.org/10.1186/s13014-021-01877-4

Similar Items

Stereotactic body radiotherapy for pelvic boost in gynecological cancer patients with local recurrence or unsuitable for intracavitary brachytherapy
by: Hsin-Yi Cheng, et al.
Published: (2021-01-01)

Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique
by: Kang Sang Won, et al.
Published: (2017-01-01)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
by: Jeong Hoon Phak, et al.
Published: (2016-03-01)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
by: Bin Qiu, et al.
Published: (2020-08-01)

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
by: Yeon Joo Kim, et al.
Published: (2018-04-01)

Stereotactic Radiotherapy Boost in Treatment of Persistent Periocular Sebaceous Carcinoma after Surgery
by: Paweł Polanowski, et al.
Published: (2023-05-01)

A feasibility study of stereotactic radiosurgery/stereotactic body radiotherapy/stereotactic ablative radiotherapy practice using tomoedge in helical tomotherapy for lung, liver, and spine targets
by: N V. N. Madhusudhana Sresty, et al.
Published: (2021-01-01)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
by: Hun Jung Kim, et al.
Published: (2015-12-01)

Abernethy malformation (Type 1B) presenting in a 6-year-old boy with hematochezia and hematuria: A case report
by: Lava Abdullah, MD, et al.
Published: (2022-09-01)

Stereotactic ablative radiotherapy for primary renal cell carcinoma
by: Daniel X. Yang, et al.
Published: (2024-01-01)

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
by: Luke Nicholls, et al.
Published: (2020-11-01)

A framework for exactrac dynamic commissioning for stereotactic radiosurgery and stereotactic ablative radiotherapy
by: Ben Perrett, et al.
Published: (2022-01-01)

Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
by: C. Belliveau, et al.
Published: (2022-12-01)

Stereotactic Radiosurgery/Radiotherapy: A Historical Review
by: Mansoureh Nabavi, et al.
Published: (2014-04-01)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
by: Ting Martin Ma, et al.
Published: (2020-12-01)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
by: Christine Kornhuber, et al.
Published: (2023-05-01)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
by: Robert Olson, et al.
Published: (2018-10-01)

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
by: Rohit K. Raj, et al.
Published: (2023-12-01)

Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
by: Sundus Yahya, et al.
Published: (2018-07-01)

Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma
by: Jongmoo Park, et al.
Published: (2019-09-01)

Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy
by: Harish N. Vasudevan, et al.
Published: (2017-06-01)

Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy
by: Jae Sik Kim, et al.
Published: (2023-10-01)

Successful Treatment of Adenoid Cystic Carcinoma with the Application of a High-Dose Stereotactic Body Radiotherapy Boost
by: Paweł Polanowski, et al.
Published: (2021-03-01)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
by: Julia Malone, BSC, et al.
Published: (2020-11-01)

High-dose stereotactic radiotherapy boost in the treatment of squamous cell carcinoma of the head and neck region
by: Paweł Polanowski, et al.
Published: (2022-06-01)

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
by: Faiez Al-Shafa, et al.
Published: (2019-06-01)

Stereotactic Radiosurgery and Stereotactic Fractionated Radiotherapy in the Management of Brain Metastases
by: Sofian Benkhaled, et al.
Published: (2024-03-01)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High Risk Localized Prostate Cancer
by: Yu-Wei eLin, et al.
Published: (2014-10-01)

Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis
by: Dong-Ho Kang, et al.
Published: (2023-11-01)

Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis
by: Jen-Fu Yang, et al.
Published: (2019-10-01)

Stereotactic Radiotherapy: An Alternative Option for Refractory Ventricular Tachycardia to Drug and Ablation Therapy
by: Wenfeng Shangguan, et al.
Published: (2022-06-01)

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial
by: David Pasquier, et al.
Published: (2023-08-01)

Developments in Stereotactic Body Radiotherapy
by: Anoop Haridass
Published: (2018-12-01)

Organizing pneumonia after stereotactic ablative radiotherapy of the lung
by: Murai Taro, et al.
Published: (2012-08-01)

Volumetric reduction of brain metastases after stereotactic radiotherapy: Prognostic factors and effect on local control
by: Naoyuki Kanayama, et al.
Published: (2022-12-01)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
by: Tyler Gutschenritter, et al.
Published: (2020-12-01)

Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
by: Tae Hoon Lee, et al.
Published: (2021-11-01)

Effective salvage of recurrent craniopharyngioma with fractionated stereotactic radiotherapy
by: Laura Burgess, et al.
Published: (2020-10-01)

Stereotactic radiotherapy: An educational narrative review
by: Agha Muhammad Hammad Khan, et al.
Published: (2024-03-01)